Approved clinical trial of Hengrui medicine shr5126

On February 24, Hengrui released a notice that shr5126 tablets were approved for clinical use and were intended to be used for the treatment of solid patients, with specific indications to be determined in clinical trials (acceptance No.: cxhl1900399, cxhl1900400) it is understood that the company submitted the clinical trial application of this product to the State Food and Drug Administration on December 5, 2019 and it was accepted Shr5126 is a new, powerful and highly selective oral A2AR antagonist, which can significantly inhibit the activity of human A2AR, inhibit the level of pCREB in the nucleus, further enhance the activation of tumor infiltrating CD8 + T cells by immunocheckpoint drugs, and inhibit the growth of tumor cells by secreting IFN γ It is intended to be used in the treatment of solid tumor patients At present, there are three oral small molecule A2AR antagonists developed at home and abroad, cpi-444 developed by Corvus, pbf-509 developed by Novartis and azd4635 developed by AstraZeneca Among them, except pbf-509 has entered the phase II clinical trial stage, others are in the phase I / IB clinical trial stage There are no similar products on the market or sales data at home and abroad Up to now, the R & D cost of the product project has been about 23.08 million yuan.